These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 28188338)
1. Characterisation of musculoskeletal tumours by multivoxel proton MR spectroscopy. Patni RS; Boruah DK; Sanyal S; Gogoi BB; Patni M; Khandelia R; Gogoi N Skeletal Radiol; 2017 Apr; 46(4):483-495. PubMed ID: 28188338 [TBL] [Abstract][Full Text] [Related]
2. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. Ma FH; Qiang JW; Cai SQ; Zhao SH; Zhang GF; Rao YM AJR Am J Roentgenol; 2015 Jun; 204(6):W724-30. PubMed ID: 26001263 [TBL] [Abstract][Full Text] [Related]
3. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors. Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615 [TBL] [Abstract][Full Text] [Related]
4. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370 [TBL] [Abstract][Full Text] [Related]
5. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors. Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357 [TBL] [Abstract][Full Text] [Related]
6. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465 [TBL] [Abstract][Full Text] [Related]
7. Qualitative 3-T Proton MR Spectroscopy for the Characterization of Musculoskeletal Neoplasms: Update on Diagnostic Performance and Indications. Gondim Teixeira PA; Ledrich M; Kauffmann F; Wamba JM; Felblinger J; Blum A; Hossu G AJR Am J Roentgenol; 2017 Jun; 208(6):1312-1319. PubMed ID: 28301222 [TBL] [Abstract][Full Text] [Related]
8. In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. Russo F; Mazzetti S; Grignani G; De Rosa G; Aglietta M; Anselmetti GC; Stasi M; Regge D Eur Radiol; 2012 May; 22(5):1131-9. PubMed ID: 22138734 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors. Sakata A; Fushimi Y; Okada T; Arakawa Y; Kunieda T; Minamiguchi S; Kido A; Sakashita N; Miyamoto S; Togashi K J Magn Reson Imaging; 2017 Sep; 46(3):732-739. PubMed ID: 28252822 [TBL] [Abstract][Full Text] [Related]
10. In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging. Zou QG; Xu HB; Liu F; Guo W; Kong XC; Wu Y Clin Radiol; 2011 Oct; 66(10):953-60. PubMed ID: 21663899 [TBL] [Abstract][Full Text] [Related]
11. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Wang CK; Li CW; Hsieh TJ; Chien SH; Liu GC; Tsai KB Radiology; 2004 Aug; 232(2):599-605. PubMed ID: 15286325 [TBL] [Abstract][Full Text] [Related]
12. In vivo proton spectroscopy of giant cell tumor of the bone. Sah PL; Sharma R; Kandpal H; Seith A; Rastogi S; Bandhu S; Jagannathan NR AJR Am J Roentgenol; 2008 Feb; 190(2):W133-9. PubMed ID: 18212197 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837 [TBL] [Abstract][Full Text] [Related]
14. [Value of 3T magnetic resonance dynamic contrast-enhanced and diffusion-weighted imaging in differential diagnosis of musculoskeletal tumors]. Qi ZH; Li CF; Ma XX; Yang H; Jiang BD; Zhang K; Yu DX Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Apr; 34(2):138-45. PubMed ID: 22776599 [TBL] [Abstract][Full Text] [Related]
15. Proton MR spectroscopy and the detection of malignancy in ovarian masses. Mansour SM; Gomma MMM; Shafik PN Br J Radiol; 2019 Sep; 92(1101):20190134. PubMed ID: 31287729 [TBL] [Abstract][Full Text] [Related]
16. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification. Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519 [TBL] [Abstract][Full Text] [Related]
17. Diffusion weighted MR imaging and proton MR spectroscopy findings of central neurocytoma with pathological correlation. Tlili-Graiess K; Mama N; Arifa N; Kadri K; Hasni I; Krifa H; Mokni M J Neuroradiol; 2014 Oct; 41(4):243-50. PubMed ID: 24238840 [TBL] [Abstract][Full Text] [Related]
18. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Fayed N; Dávila J; Medrano J; Olmos S Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889 [TBL] [Abstract][Full Text] [Related]
19. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas. Fayed N; Morales H; Modrego PJ; Pina MA Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275 [TBL] [Abstract][Full Text] [Related]
20. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Yang D; Korogi Y; Sugahara T; Kitajima M; Shigematsu Y; Liang L; Ushio Y; Takahashi M Neuroradiology; 2002 Aug; 44(8):656-66. PubMed ID: 12185543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]